Balyasny Asset Management
ARCT icon

Balyasny Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Balyasny Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,219,000
Closed -$22.5M – 3062
2025
Q3 		$22.5M Buy
1,219,000
+1,128,800
+1,251% +$18.1M 0.03% 666
2025
Q2 		$1.17M Buy
+90,200
New +$1.07M ﹤0.01% 1988
2020
Q3 		– Sell
-30,000
Closed -$1.4M – 1269
2020
Q2 		$1.4M Buy
+30,000
New +$1.03M 0.01% 776

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Balyasny Asset Management's ARCT Position: Q4 2025 in Review

Balyasny Asset Management sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 964,985 shares — an estimated $17.8M sold.

Balyasny Asset Management first reported a position in ARCT in Q2 2015 and held it in 15 quarters. The position peaked at $17.8M in Q3 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Balyasny Asset Management reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 964,985 Arcturus Therapeutics shares in Q4 2025, an estimated $17.8M.
  • Balyasny Asset Management first reported a position in Arcturus Therapeutics in Q2 2015 and held it in 15 quarters.
  • Balyasny Asset Management's Arcturus Therapeutics position peaked at $17.8M in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.